U.S. Markets open in 4 hrs 52 mins

Synergy Pharmaceuticals Inc. (SGYP)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
4.74+0.15 (+3.27%)
At close: 4:00PM EDT
People also watch

Synergy Pharmaceuticals Inc.

420 Lexington Avenue
Suite 2012
New York, NY 10170
United States

IndustryDrug Manufacturers - Other
Full Time Employees92

Key Executives

Dr. Gary S. Jacob Ph.D.Chairman, Chief Exec. Officer & Pres844.01kN/A70
Dr. Kunwar Shailubhai Ph.D., M.B.A.Chief Scientific Officer and Exec. VP524.29kN/A59
Dr. Patrick H. Griffin M.D., FACPExec. VP & Chief Medical Officer607.65kN/A62
Mr. Troy Hamilton PharmDExec. VP & Chief Commercial Officer567.5kN/A45
Mr. Bernard F. Denoyer CPA, M.B.A.Exec. Officer331.19kN/A69
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin analog that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.

Corporate Governance

Synergy Pharmaceuticals Inc.’s ISS Governance QualityScore as of June 2, 2017 is 8. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 2; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.